Market research
AXGT Sio Gene Therapies, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 99M
- P/E ratio
- Not available
- Analyst target
- 8.5
- Dividend yield
- 0.0%
- Beta
- 1.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BMG0750W2037
- Market cap
- 99M
- P/E ratio
- Not available
- Analyst target
- 8.5
- Dividend yield
- 0.0%
- Beta
- 1.58
About
About Sio Gene Therapies, Inc
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AXGT discussion.
5 years, 4 months ago
Sio Gene Therapies, Inc is currently in a long term downtrend where the price is trading 15.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Sio Gene Therapies, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 25.1% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.4% to $-12M since the same quarter in the previous year.
Based on the above factors, Sio Gene Therapies, Inc gets an overall score of 3/5.